Year: 2023

CHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday, December 14, 2023 via Zoom. Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 – 2:45 p.m. ET. Discussions will explore lessons learned from the recent COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the current state of research, development,...

SINGAPORE, Dec. 11, 2023 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, today announced the launch of a full AI Education Ecosystem for Governments, Companies, Universities and Schools in Partnership with FatBrain AI. FatBrain AI is an AI-driven SAAS company (OTCMKTS: LZGI), co-founded by serial entrepreneur, Peter B. Ritz, and executive chaired by Michael T. Moe, Founder and CEO of GSV, ASU-GSV Summit, GSV Ventures, an early investor in 16 out of 30 Edtech companies including Coursera, Chegg, ClassDojo, Course Hero, Masterclass, and Guild Education. FatBrain AI delivers peer intelligence and hierarchical insights to connect GOV, F500 and SMEs (Companies with 500 or less employees) with a variety of sector-specific SAAS solutions....

Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced today that it plans to develop nimacimab, the Company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity. The Company has filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 2 clinical study of nimacimab in patients with obesity and chronic kidney disease. Nimacimab is a negative-allosteric modulating antibody...

Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNH Majority of patients remained transfusion free over the long term Zero cases of meningococcal infection observed over three years in this analysis Data shared during an oral presentationWALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI® (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) for up to three years. The data were reported during an oral presentation at the American Society of Hematology (ASH) Annual Meeting. “These results show that treatment with EMPAVELI can help PNH patients achieve rapid and sustained control of their disease over the long term,”...

HESPERIA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, clarifies that Stefan Selig’s appointment to the Company’s board of directors commenced as of December 11, 2023. The company had previously announced that Selig’s appointment commenced on December 5, 2023. About 5E Advanced Materials, Inc. 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) is focused on becoming a vertically integrated global leader and supplier of boron specialty and advanced materials, complemented by lithium co-product production. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, food and...

Vincent J. O’Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates. Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product...

Canoo Inc. AttachmentJustin, Texas, Dec. 11, 2023 (GLOBE NEWSWIRE) — Canoo Inc. (Nasdaq: GOEV), a leading high-tech advanced mobility company, today announced Michael Carter as Chief People Officer.  Carter will be responsible for helping the company through its growth and scaling manufacturing in Oklahoma.  “We’re excited to welcome Michael to the Canoo team,” said Tony Aquila, Investor, Executive Chairman, and CEO at Canoo. “This important next phase in our journey requires ramping up our manufacturing team in Oklahoma. Michael’s skillset is connected to the most important things we have to get done in 2024.”  Carter has more than two decades of human resources leadership experience from Fortune 500 and Silicon Valley technology companies, including Cisco, Intel, and Qualcomm. Prior to joining Canoo, Carter was vice...

EDMONTON, Alberta, Dec. 11, 2023 (GLOBE NEWSWIRE) — TSX, NYSE: STN Stantec Inc. (“Stantec”), a global leader in sustainable design and engineering, announced today that it has received approval from the Toronto Stock Exchange ( the “TSX”) respecting the renewal of its Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB documentation filed with the TSX, Stantec may purchase up to 2,281,339 common shares, representing approximately 2% of Stantec’s 114,066,995 issued and outstanding common shares as of December 1, 2023. The purchases may commence on December 13, 2023 and will terminate no later than December 12, 2024. Except for block purchases permitted under the rules and policies of the TSX, the number of shares to be purchased per day will not exceed 88,772 or approximately 25% of the average daily trading volume for the...

LONDON, UK and ATLANTA, Dec. 11, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that U.K.-based ecommerce brand AYBL, an innovative online retailer of activewear, has transformed its warehouse and fulfillment capabilities by replacing paper-based picking and manual fulfillment practices with Descartes’ ecommerce warehouse management system (WMS). Using the solution to improve picking efficiency and accuracy, AYBL has doubled its fulfillment capacity with existing staff and can seamlessly scale to fulfill over 70,000 orders a day during peak season. “To become a leader in ecommerce within the U.K. you have to deliver on customer promises and build loyalty, which means you have to be able to rely on your warehouse and fulfillment...